MEDIPOST Co., Ltd.
Financials
Valuation Metrics
MEDIPOST Co., Ltd.'s Market Cap is ₩3866B. At end of 2025 it was ₩7131B. Ranked #579 of 2,436 in KR market (top 24%), #227 of 1,649 on KOSDAQ (top 14%), #17 of 96 in Health Care Equipment & Services (top 18%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 386.56B KRW | KR#579/2,436 Sec#17/96 |
| Revenue | 73.90B KRW | KR#1,574/2,436 Sec#44/96 |
| Net Income | -80.19B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 577.70B KRW | KR#677/2,436 Sec#10/96 |
| Net Assets | 241.25B KRW | KR#825/2,436 Sec#18/96 |
| Employees | 648 | KR#386/2,436 Sec#5/96 |
| Value | ||
| P/B | 1.60x | KR#1,756/2,436 Sec#57/96 |
| P/S | 5.23x | KR#2,129/2,436 Sec#71/96 |
| FCF Yield | -15.54% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -33.24% | KR#2,191/2,436 Sec#79/96 |
| ROA | -13.88% | KR#2,156/2,436 Sec#75/96 |
| Op. Margin | -96.31% | KR#2,307/2,436 Sec#84/96 |
| Revenue Growth | 1.24% | KR#1,355/2,436 Sec#61/96 |
| Financial Health | ||
| Debt Ratio | 239.46% | KR#1,951/2,436 Sec#85/96 |
| Total Debt | 162.97B KRW | KR#555/2,436 Sec#9/96 |
| FCF | -60.06B KRW | KR#2,105/2,436 Sec#83/96 |
| Cash | 102.54B KRW | KR#459/2,436 Sec#4/96 |
| Current Ratio | 1.08x | KR#1,733/2,436 Sec#80/96 |
| Performance | ||
| 1Y Return | -3.90% | KR#1,128/2,436 Sec#30/96 |
| 1M Return | 7.76% | KR#1,380/2,436 Sec#57/96 |
| From 52W High | -66.12% | KR#2,120/2,436 Sec#77/96 |
| 1Y MDD | -73.14% | KR#2,069/2,436 Sec#76/96 |
| Trading | ||
| Volume | 216,800 shares | KR#1,226/2,436 Sec#49/96 |
| Foreign Own. | 3.24% | KR#979/2,436 Sec#36/96 |
| Per Share | ||
| EPS | -2,061 KRW | KR—/2,436 Sec—/96 |
| BPS | 6,153 KRW | KR#1,285/2,436 Sec#30/96 |
Company Info
Medipost, established in 2000 and listed on KOSDAQ in 2005, specializes in umbilical cord blood banking and stem cell therapy development. The company operates an umbilical cord blood bank, sells the degenerative arthritis treatment Cartistem, and develops umbilical cord blood-derived stem cell therapies. It also engages in the health functional food business, offering multivitamins and probiotics. Medipost is headquartered in Seongnam-si, Gyeonggi-do, and actively expands its market reach through awareness campaigns, global clinical trials for Cartistem, and diversified online marketing channels.